ALNY stock forecast, quote, news & analysis
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics... Show more
Alnylam Pharmaceuticals (ALNY) Stock Analysis: Earnings Anticipation Amid Recent Pullback
Key Takeaways
- ALNY shares have pulled back in recent weeks, reflecting valuation concerns despite positive clinical data.
- New data at recent cardiology conference bolstered vutrisiran (Amvuttra) in ATTR-CM (transthyretin amyloidosis with cardiomyopathy).
- Q1 2026 earnings due soon, with consensus expecting EPS of $1.50 and revenue around $1.13 billion, up sharply year-over-year.
- Analyst consensus remains Strong Buy, with average price target exceeding $450.
- 2026 guidance highlights robust TTR (transthyretin) sales growth to $4.4-4.7 billion.
Current Market Snapshot
In recent trading sessions, Alnylam Pharmaceuticals (ALNY) stock has faced downward pressure, retreating from prior peaks within the biotech sector's volatile landscape. The shares have consolidated in the low $300s amid investor scrutiny of valuations and macroeconomic headwinds affecting growth stocks. Trading volume has remained steady, signaling cautious positioning ahead of key catalysts. Positive sentiment around the company's RNAi (RNA interference) pipeline, particularly in rare diseases, provides a supportive undercurrent, though broader market rotations have weighed on performance. Investors eye upcoming disclosures for confirmation of sustained momentum in commercial products like Amvuttra.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of over 25 top-performing AI trading bots from a library of more than 350 bots that analyze and trade thousands of tickers across stocks, ETFs, and cryptocurrencies. These bots employ diverse strategies, including technical and fundamental analysis, with timeframes from 5-minute scalps to longer-term plans, and risk profiles spanning low to high volatility. Categorized as AI Trading Signal Agents, Virtual Agents with customizable risk management, or Brokerage Agents, they offer real-time signals without minimum balances for some. This dynamic section highlights bots best suited to prevailing market conditions, featuring varied performances tailored to different trading styles. Trending AI Robots provide an efficient way for traders to leverage AI insights across assets like ALNY.
Recent Developments Driving ALNY Price Action
Over the past 30 days, Alnylam Pharmaceuticals (ALNY) has navigated a mix of clinical advancements and market pressures, contributing to a roughly 9% decline in share price. A key highlight was the March 30 presentation at ACC.26, the American College of Cardiology conference, where new analyses reinforced the benefits of vutrisiran, marketed as Amvuttra, in ATTR-CM patients. Data showed sustained efficacy in reducing cardiac biomarkers and improving quality of life, positioning it as a potential first-line therapy for wild-type or hereditary ATTR-CM. Additional insights on zilebesiran demonstrated promising blood pressure reductions in hypertension trials, expanding Alnylam's cardiovascular footprint.
Earlier, on March 24, Alnylam announced a strategic collaboration with Viz.ai to advance ATTR-CM care, alongside support for the American Heart Association, enhancing diagnostic and treatment pathways. These developments initially supported modest gains but were overshadowed by valuation reassessments.
On April 16, the company confirmed a webcast for its Q1 2026 earnings on April 30, heightening anticipation. Analysts forecast EPS of $1.50 and revenue near $1.13 billion, reflecting over 90% year-over-year growth driven by Amvuttra and other RNAi therapies like Givlaari and Oxlumo. The stock slid nearly 4% that day amid lingering valuation concerns post-analyst adjustments, including Truist Securities trimming its target to $505 from $515 while maintaining Buy.+slides+4%+as+valuation+concerns+linger+after+recent+analyst+reset)
Despite the pullback, broader analyst sentiment holds firm, with 26 firms rating it Moderate Buy and an average target of $472.78, implying significant upside. Biotech sector rotations and interest rate sensitivities amplified the decline, but pipeline validation has preserved investor interest ahead of earnings confirmation of profitability progress.
2026 Outlook and Key Factors to Monitor
As Alnylam Pharmaceuticals advances through 2026, focus remains on executing strong guidance for transthyretin (TTR) sales of $4.4-4.7 billion, fueled by Amvuttra uptake in ATTR-CM and polyneuropathy. Achieving profitability milestones will be pivotal, supported by operational efficiencies and a maturing commercial portfolio including Onpattro, Givlaari, and Oxlumo.
Investors should track pipeline catalysts, such as zilebesiran Phase 3 readouts in hypertension and further ATTR expansions. Regulatory progress for new indications and label updates could drive adoption. Competitive dynamics in RNAi therapeutics, manufacturing scale-up, and reimbursement landscapes warrant attention. Macro factors like healthcare policy shifts and biotech funding environment may influence sentiment. Long-term growth hinges on innovation in rare diseases and cardiovascular space, balanced against R&D spend and cash burn.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
ALNY in +6.12% Uptrend, rising for three consecutive days on June 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ALNY advanced for three days, in of 307 cases, the price rose further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on June 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for ALNY turned negative on June 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ALNY broke above its upper Bollinger Band on May 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALNY entered a downward trend on June 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (35.088) is normal, around the industry mean (18.720). P/E Ratio (71.068) is within average values for comparable stocks, (36.072). Projected Growth (PEG Ratio) (0.483) is also within normal values, averaging (1.682). ALNY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (9.025) is also within normal values, averaging (357.550).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of therapeutics based on RNA interference
Industry Biotechnology